STAT+: Axsome drug reduces agitation in Alzheimer’s patients, data show
A drug developed by Axsome Therapeutics significantly reduced a common side effect of Alzheimer’s disease — agitation — the company announced Monday.
The therapy, AXS-05, met its primary goal of delaying time to relapse and preventing patients from relapsing. Patients taking the drug had a 3.6-fold lower risk of relapse overall, compared to placebo.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: Axsome drug reduces agitation in Alzheimer’s patients, data show »
